LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.

Employees

140

Sector

Advanced Medical Equipment & Technology

Calendar

03-31 - Earnings release - Q4 2025

More about the company

Quotes

Date	Price	Change	Volume
16/03/26	10.26 $	+4.16%	227,166
13/03/26	9.850 $	-15.63%	258,993
12/03/26	11.68 $	-0.98%	57,432
11/03/26	11.79 $	+0.86%	14,666
10/03/26	11.69 $	-1.68%	19,578

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

10.26USD

Average target price

15.00USD

Spread / Average Target

+46.20%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 20:00:00 16/03/2026 GMT			5-day change	1st Jan Change
10.26 ^USD	+4.16%		-13.71%	-11.78%

04:31am	Alcon Drops Lensar Merger Over US Regulatory Opposition, Delay	MT
03-16	Lensar announces termination of merger agreement with Alcon Research, LLC	RE

Capitalization	123M 107M 96.65M 92.21M 168M 11.31B 174M 1.15B 456M 5.41B 460M 450M 19.52B	P/E ratio 2025 *	-3.65x	P/E ratio 2026 *	-82.1x
Enterprise value	123M 107M 96.65M 92.21M 168M 11.31B 174M 1.15B 456M 5.41B 460M 450M 19.52B	EV / Sales 2025 *	1.95x	EV / Sales 2026 *	1.44x
Free-Float	80.43%	Yield 2025 *	-	Yield 2026 *	-

04:31am	Alcon Drops Lensar Merger Over US Regulatory Opposition, Delay	MT
03-16	Lensar announces termination of merger agreement with Alcon Research, LLC	RE
03-16	Lensar and Alcon Agree to Terminate Merger	DJ
03-16	Lensar, Alcon Terminate Merger Agreement	MT
03-16	Alcon and Lensar agree to terminate merger agreement	RE
03-15	Alcon Research, LLC cancelled the acquisition of LENSAR, Inc. from a group of shareholders.	CI
03-13	Lensar, Inc. Enters into Priority Credit Line Agreement with Wells Fargo Bank, N.A. Permitting Borrowings Up to $9.2 Million	CI
02-26	Lensar® provides update on pending acquisition by Alcon	RE
11-06	LENSAR, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-06	LENSAR Q3 net loss widens	RE
02/09/25	Lensar reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
13/08/25	Alcon Poised to Deliver Q2 Sales Beat, Full-Year Guidance Raise, Needham Says	MT
07/08/25	LENSAR, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

13/08/25	Alcon Poised to Deliver Q2 Sales Beat, Full-Year Guidance Raise, Needham Says	MT
25/03/25	BTIG Research Downgrades LENSAR to Neutral From Buy	MT
24/03/25	Lake Street Downgrades LENSAR to Hold From Buy, Price Target is $15	MT
22/11/21	BTIG Starts LENSAR at Buy With $15 Price Target	MT
24/02/21	LENSAR : SVB Leerink Starts LENSAR at Outperform With $20 Price Target	MT

LENSAR, Inc. Share Price

Equities

LNSR

US52634L1089

Advanced Medical Equipment & Technology

Valuation: LENSAR, Inc.

Chart: LENSAR, Inc.

Latest news: LENSAR, Inc.

Last Transcript: LENSAR, Inc.

Analysts' recommendations: LENSAR, Inc.

Press Releases: LENSAR, Inc.

News in other languages: LENSAR, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: LENSAR, Inc.

ETFs: LENSAR, Inc.

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

03-16	LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC	AQ
02-25	LENSAR® Provides Update on Pending Acquisition by Alcon	AQ
11-06	LENSAR : LNSR Corporate Presentation November 2025	PU
11-06	LENSAR® Reports Third Quarter 2025 Results and Provides Business Update	AQ
02/09/25	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ

03-16	Alcon et Lensar mettent fin à leur accord de fusion, obstacles réglementaires
03-16	Alcon und Lensar beenden den zuvor angekündigten Fusionsvertrag
24/03/25	Alcon : accord pour l'acquisition de Lensar
24/03/25	Alcon acquiert la société américaine Lensar
24/03/25	Alcon übernimmt Medizintechnikunternehmen Lensar für bis zu 430 Millionen Dollar

1 day	+4.16%
1 week	-13.71%
Current month	-14.29%
1 month	-16.11%
3 months	-14.93%
6 months	-16.92%
Current year	-11.78%

1 week	9.1	11.8
1 month	9.1	12.23
Current year	9.1	12.94
1 year	9.1	17.31
3 years	1.8	17.31
5 years	1.8	17.31
10 years	1.8	17.31

Manager	Title	Age	Since
Nicholas Curtis CEO	Chief Executive Officer	71	31/01/2012
Thomas Staab DFI	Director of Finance/CFO	58	30/04/2020
Alan Connaughton COO	Chief Operating Officer	54	31/12/2007

Director	Title	Age	Since
Nicholas Curtis BRD	Director/Board Member	71	31/01/2012
Bill Link CHM	Chairman	80	07/11/2017
Richard Lindstrom BRD	Director/Board Member	78	01/02/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
LENSAR, INC.	+4.16%	-13.71%	-32.19%	+215.69%	118M
THERMO FISHER SCIENTIFIC, INC.	+1.21%	-7.84%	-9.97%	-15.63%	173B
INTUITIVE SURGICAL, INC.	+2.39%	-2.05%	-0.20%	+101.02%	168B
DANAHER CORPORATION	+2.17%	-3.73%	-9.18%	-23.24%	132B
BOSTON SCIENTIFIC CORPORATION	+0.95%	-2.93%	-28.17%	+44.49%	103B
SIEMENS HEALTHINEERS AG	-1.11%	-4.12%	-26.59%	-23.97%	49.5B
EDWARDS LIFESCIENCES CORPORATION	+2.14%	-0.83%	+20.59%	+2.01%	47.52B
RESMED, INC.	-0.10%	-8.82%	+2.88%	+9.15%	33.48B
GE HEALTHCARE TECHNOLOGIES INC.	+1.98%	-4.57%	-11.96%	-5.81%	32.25B
AGILENT TECHNOLOGIES, INC.	+0.29%	-4.12%	-7.72%	-18.26%	31.51B
Average	+1.43%	-5.27%	-10.25%	+28.55%	76.96B
Weighted average by Cap.	+1.45%	-4.30%	-8.75%	+18.46%

	2025 *	2026 *
Net sales	62.7M 54.61M 49.45M 47.17M 85.81M 5.79B 88.97M 588M 233M 2.77B 235M 230M 9.99B	85.1M 74.12M 67.11M 64.03M 116M 7.86B 121M 797M 317M 3.76B 319M 313M 13.56B
Net income	-33.6M -29.27M -26.5M -25.28M -45.99M -3.1B -47.68M -315M -125M -1.48B -126M -123M -5.35B	-1.5M -1.31M -1.18M -1.13M -2.05M -138M -2.13M -14.06M -5.59M -66.25M -5.63M -5.51M -239M
Net Debt	-	-